Literature DB >> 22363141

Gastric mucosa-associated lymphoid tissue lymphomas and Helicobacter pylori infection: a Colombian perspective.

Sally Yepes1, Maria Mercedes Torres, Carlos Saavedra, Rafael Andrade.   

Abstract

AIM: To assess the significance of chromosome translocation t(11;18)(q21;q21), B-cell lymphoma 10 (BCL-10) protein and Helicobacter pylori (H. pylori) infection in gastric mucosa-associated lymphoid tissue (MALT) lymphoma in Colombia.
METHODS: Fifty cases of gastric MALT lymphoma and their respective post-treatment follow-up biopsies were examined to assess the presence of the translocation t(11;18)(q21;q21) as identified by fluorescence in situ hybridization; to detect protein expression patterns of BCL10 using immunohistochemistry; and for evaluation of tumor histology to determine the correlation of these factors and resistance to H. pylori eradication.
RESULTS: Infection with H. pylori was confirmed in all cases of gastric MALT lymphoma in association with chronic gastritis. Bacterial eradication led to tumor regression in 66% of cases. The translocation t(11;18)(q21;q21) was not present in any of these cases, nor was there evidence of tumor transformation to diffuse large B-cell lymphoma. Thirty-four percent of the patients showed resistance to tumor regression, and within this group, 7 cases, representing 14% of all those analyzed, were considered to be t(11;18)(q21;q21)-positive gastric MALT lymphomas. Protein expression of BCL10 in the nucleus was associated with the presence of translocation and treatment resistance. Cases that were considered unresponsive to therapy were histologically characterized by the presence of homogeneous tumor cells and a lack of plasmacytic differentiation. Responder cases exhibited higher cellular heterogeneity and a greater frequency of plasma cells.
CONCLUSION: Both t(11;18)(q21;q21)-positive MALT lymphoma cases and those with nuclear BCL10 expression are considered resistant to H. pylori eradication. It is suggested that chronic antigenic stimulation is not a dominant event in resistant cases.

Entities:  

Keywords:  18)(q21; B-cell lymphoma 10; Helicobacter pylori; Mucosa-associated lymphoid tissue lymphoma; Treatment; q21); t(11

Mesh:

Substances:

Year:  2012        PMID: 22363141      PMCID: PMC3281227          DOI: 10.3748/wjg.v18.i7.685

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  22 in total

1.  Translocation t(11;18) absent in early gastric marginal zone B-cell lymphoma of MALT type responding to eradication of Helicobacter pylori infection.

Authors:  B Alpen; A Neubauer; J Dierlamm; P Marynen; C Thiede; E Bayerdörfer; M Stolte
Journal:  Blood       Date:  2000-06-15       Impact factor: 22.113

2.  Gastric marginal zone lymphoma of MALT type: ESMO clinical recommendations for diagnosis, treatment and follow-up.

Authors:  E Zucca; M Dreyling
Journal:  Ann Oncol       Date:  2008-05       Impact factor: 32.976

3.  Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication.

Authors:  Thomas Wündisch; Christian Thiede; Andrea Morgner; Astrid Dempfle; Annette Günther; Hongxiang Liu; Hongtao Ye; Ming-Qing Du; Theo D Kim; Ekkehard Bayerdörffer; Manfred Stolte; Andreas Neubauer
Journal:  J Clin Oncol       Date:  2005-10-03       Impact factor: 44.544

Review 4.  Gastric MALT lymphoma: a model of chronic inflammation-induced tumor development.

Authors:  Xavier Sagaert; Eric Van Cutsem; Gert De Hertogh; Karel Geboes; Thomas Tousseyn
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-05-04       Impact factor: 46.802

Review 5.  Molecular pathogenesis of MALT lymphoma: two signaling pathways underlying the antiapoptotic effect of API2-MALT1 fusion protein.

Authors:  M Nakagawa; M Seto; Y Hosokawa
Journal:  Leukemia       Date:  2006-06       Impact factor: 11.528

6.  The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North America.

Authors:  Ellen D Remstein; Ahmet Dogan; Richard R Einerson; Sarah F Paternoster; Stephanie R Fink; Mark Law; Gordon W Dewald; Paul J Kurtin
Journal:  Am J Surg Pathol       Date:  2006-12       Impact factor: 6.394

Review 7.  Eradication therapy for Helicobacter pylori in patients with gastric MALT lymphoma: a pooled data analysis.

Authors:  Angelo Zullo; Cesare Hassan; Alessandro Andriani; Francesca Cristofari; Vincenzo De Francesco; Enzo Ierardi; Silverio Tomao; Sergio Morini; Dino Vaira
Journal:  Am J Gastroenterol       Date:  2009-06-16       Impact factor: 10.864

Review 8.  Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma.

Authors:  Angelo Zullo; Cesare Hassan; Francesca Cristofari; Alessandro Andriani; Vincenzo De Francesco; Enzo Ierardi; Silverio Tomao; Manfred Stolte; Sergio Morini; Dino Vaira
Journal:  Clin Gastroenterol Hepatol       Date:  2009-07-22       Impact factor: 11.382

9.  Translocation t(11;18)(q21;q21) in gastric B-cell lymphomas.

Authors:  Sonia Toracchio; Hiroyoshi Ota; Daphne de Jong; Andrew Wotherspoon; Massimo Rugge; David Y Graham; Amir Samani; Hala M T El-Zimaity
Journal:  Cancer Sci       Date:  2009-03-23       Impact factor: 6.716

10.  Clinicopathological comparison of the World Health Organization/Wotherspoon score to the Groupe d'Etude des Lymphomes de l'Adult grade for the post-treatment evaluation of gastric mucosa-associated lymphoid tissue lymphoma.

Authors:  Eisuke Shiozawa; Tomoko Norose; Kazuhiro Kaneko; Toshiko Yamochi-Onizuka; Masafumi Takimoto; Michio Imawari; Hidekazu Ota
Journal:  J Gastroenterol Hepatol       Date:  2008-11-20       Impact factor: 4.029

View more
  2 in total

Review 1.  Helicobacter pylori in gastric malignancies.

Authors:  Abhishek Bhandari; Sheila E Crowe
Journal:  Curr Gastroenterol Rep       Date:  2012-12

Review 2.  Role of Helicobacter pylori in gastric mucosa-associated lymphoid tissue lymphomas.

Authors:  Marta-Isabel Pereira; José Augusto Medeiros
Journal:  World J Gastroenterol       Date:  2014-01-21       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.